{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T05:05:48Z","timestamp":1726290348462},"reference-count":115,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2020,3,3]]},"DOI":"10.1080\/13543784.2020.1724281","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T15:16:30Z","timestamp":1580310990000},"page":"273-283","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1"],"prefix":"10.1080","volume":"29","author":[{"given":"Hanh Thi","family":"Pham","sequence":"first","affiliation":[{"name":"McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subin","family":"Yoo","sequence":"additional","affiliation":[{"name":"McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Mespl\u00e8de","sequence":"additional","affiliation":[{"name":"McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S37069"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000467"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2018.07.014"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2008.04.007"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159517"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05036-14"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz271"},{"key":"cit0008","author":"Schurmann D","year":"2020","journal-title":"Lancet HIV"},{"key":"cit0009","unstructured":"Islatravir (mk-8591) with doravirine and lamivudine in participants infected with human immunodeficiency virus type 1 (mk-8591-011) (drive2simplify). U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03272347?term=NCT03272347&draw=2&rank=1"},{"key":"cit0010","volume-title":"Safety and pk of subutaneous gs-6207, a novel hiv-1 capsid inhibitor","author":"Sager JE","year":"2020"},{"key":"cit0011","volume-title":"Discovery of novel potent hiv capsid inhibitors with long-acting potential","author":"Tse WC"},{"key":"cit0012","unstructured":"Study to evaluate the safety and efficacy of gs-6207 in combination with other antiretroviral agents in people living with hiv (calibrate). U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04143594."},{"key":"cit0013","unstructured":"Study to evaluate the safety and efficacy of gs-6207 in combination with an optimized background regimen in heavily treatment experienced participants living with hiv-1 infection with multidrug resistance. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04150068?term=gs-6207&draw=2&rank=1."},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000491"},{"key":"cit0015","unstructured":"A combination efficacy study in africa of two DNA-mva-env protein or DNA-env protein hiv-1 vaccine regimens with prep (prepvacc). U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04066881"},{"key":"cit0016","unstructured":"Study to assess safety and ability to induce immune responses of hiv-1 vaccines m3 and m4 given alone or in combination in hiv-infected adults (m&m). U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03844386"},{"key":"cit0017","unstructured":"Hiv-1-gag conserved-element DNA vaccine as therapeutic vaccination in hiv-infected persons with viral suppression on antiretroviral therapy. U.S. National Libray of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03560258"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000475"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12075"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0972"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000144"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh428"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200210180-00006"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1038\/nm1244"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz2686"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0412-8"},{"key":"cit0027","unstructured":"3bnc117 and 10-1074 in art-treated individuals. U.S. National Libray of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03526848?term=3BNC117%2C+10-1074&draw=2&rank=4"},{"key":"cit0028","unstructured":"Combination therapy with 3bnc117 and 10-1074 in hiv-infected individuals. U.S. National Libray of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03571204"},{"key":"cit0029","unstructured":"Dual bnab treatment in children. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03707977"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1038\/nature14411"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5752"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4268"},{"key":"cit0033","unstructured":"A phase 1\/2a study of pgt121, vrc07-523ls and pgdm1400 monoclonal antibodies in hiv-uninfected and hiv-infected adults. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03721510"},{"key":"cit0034","unstructured":"A clinical trial of pgdm1400 and pgt121 and vrc07-523ls monoclonal antibodies in hiv-infected and hiv-uninfected adults. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03205917"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan8630"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.18.10367"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802264"},{"key":"cit0038","unstructured":"Study to evaluate safety and efficacy of ub-421 antibody in hiv-1 infected adults. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01668043"},{"key":"cit0039","unstructured":"Study to evaluate safety and pharmacokinetics of ub-421 antibody in hiv-1 infected adults. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01140126?term=ub-421&draw=2&rank=4"},{"key":"cit0040","unstructured":"To investigate the safety and efficacy of ub-421 monotherapy in hiv infected adults. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02369146"},{"key":"cit0041","unstructured":"The study to evaluate the safety of ub-421 in combination with antiretroviral therapy (art) and the efficacy in reduction of hiv viral load and proviral DNA as compared to art alone in art-experienced viremic hiv-1 patients. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04041362"},{"key":"cit0042","unstructured":"Ub-421 combine with optimized background therapy regimen in multi-drug resistant hiv-1 infection patients. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03164447?term=ub-421&draw=2&rank=7"},{"key":"cit0043","unstructured":"The hiv functional cure potential of ub-421 in art stabilized hiv-1 patients. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03743376"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag1276"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw8562"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav6695"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw7765"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax3447"},{"key":"cit0049","volume-title":"Seeking suppression in havarti: viremia and t cells after vedolizumab and ati in hiv\/art","author":"McGuinty M","year":"2019"},{"key":"cit0050","unstructured":"Vedolizumab (anti-alpha4beta7) in subjects with hiv infection undergoing analytical treatment interruption. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02788175"},{"key":"cit0051","unstructured":"Vedolizumab treatment in antiretroviral drug treated chronic hiv infection (havarti). U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03147859"},{"key":"cit0052","unstructured":"A hiv vaccine trial in individuals who started antiretrovirals during primary or chronic infection (ehva t02). U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04120415"},{"key":"cit0053","unstructured":"Vedolizumab treatment in hiv-infected subjects without previous antiretroviral therapy. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03577782"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02109"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01786-19"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.10.101"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000281"},{"key":"cit0058","volume-title":"A randomised controlled trial comparing the impact of antiretroviral therapy (art) with a \u2018kick-and-kill\u2019 approach to art alone on hiv reservoirs in individuals with primary hiv infection (phi); river trial","author":"Fidler S","year":"2018"},{"key":"cit0059","unstructured":"Evaluating a combination of immune-based therapies to achieve a remission of hiv infection (hivacar). U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619278"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1177\/095632020101200301"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.1.1.83"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000444"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8848"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000830"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir615"},{"key":"cit0066","first-page":"CD009818","volume":"5","author":"Onwumeh J","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0067","unstructured":"Therapeutic vaccine for hiv. U.S. National Libray of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01859325"},{"key":"cit0068","unstructured":"Therapeutic vaccination in treated hiv disease. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03606213"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002288"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis383"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-465625"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000894"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1806695115"},{"key":"cit0074","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Davis Z","year":"2018"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00806.x"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1038\/ni1515"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005349"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4113"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005761"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.112"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02060"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001849"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1038\/nature07662"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.8.5439"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08798-7"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198158"},{"key":"cit0088","unstructured":"A dose-escalation study of mdx-010 administered monthly as immunotherapy in subjects infected with human immunodeficiency virus (hiv). U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03407105"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix191"},{"key":"cit0090","unstructured":"Safety and immune response of bms-936559 in hiv-infected people taking combination antiretroviral therapy. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02028403"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6737"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000562"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx696"},{"key":"cit0094","unstructured":"Safety and immunotherapeutic activity of an anti-pd-1 antibody (cemiplimab) in participants with hiv-1 on suppressive cart. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03787095"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211112"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.2.980"},{"key":"cit0097","unstructured":"The effect of ixazomib on the latent hiv reservoir. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02946047"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-5987-2_9"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1038\/nri3875"},{"key":"cit0100","unstructured":"Evaluating the safety and immunogenicity of hiv-1 bg505 sosip.664 gp140 with tlr agonist and\/or alum adjuvants in healthy, hiv-uninfected adults. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04177355"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02166-16"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-119"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.04.019"},{"key":"cit0104","unstructured":"Combining tlr9 agonist with bnabs for reservoir reduction and immunological control of hiv (titan). U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03837756"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024793"},{"key":"cit0106","unstructured":"Cannabinoids in plwhiv on effective art. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03550352"},{"key":"cit0107","unstructured":"Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in hiv-1 individuals. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01836068"},{"key":"cit0108","unstructured":"Hiv-1 specific t -cells (hst-neets) for hiv-infected individuals (resist). U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03485963"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02993"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.4161\/hv.25876"},{"key":"cit0111","unstructured":"N-803 combined with the broadly neutralizing antibodies plus or minus hank cells for hiv. U.S. National Library of Medicine. [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04144335"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1430570"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.002"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122089"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226724"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2020.1724281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T05:21:41Z","timestamp":1620451301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2020.1724281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,3]]}},"alternative-id":["10.1080\/13543784.2020.1724281"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2020.1724281","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}